[go: up one dir, main page]

AR066782A1 - Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida - Google Patents

Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida

Info

Publication number
AR066782A1
AR066782A1 ARP080102286A ARP080102286A AR066782A1 AR 066782 A1 AR066782 A1 AR 066782A1 AR P080102286 A ARP080102286 A AR P080102286A AR P080102286 A ARP080102286 A AR P080102286A AR 066782 A1 AR066782 A1 AR 066782A1
Authority
AR
Argentina
Prior art keywords
muscle relaxant
neurotoxic component
botulinic
oxine
stable
Prior art date
Application number
ARP080102286A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07010912A external-priority patent/EP1997509A1/en
Priority claimed from EP07020025A external-priority patent/EP2048156A1/en
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR066782A1 publication Critical patent/AR066782A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Proceso para proporcionar un relajante muscular a temperaturas superiores a 20°C, donde dicho relajante muscular es una composicion seca solida que comprende el componente neurotoxico de toxina botulínica libre de proteínas formadoras de complejos. Reivindicacion 9: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composicion es un liofilizado del componente neurotoxico de toxina botulínica. Reivindicacion 10: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composicion comprende además sacarosa y/o seroalbumina humana. Reivindicacion 11: El proceso de acuerdo con cualquiera de las reivindicaciones precedentes, donde la composicion comprende además por lo menos un componente seleccionado del grupo formado por un crioprotector, un estabilizante, un buffer del pH, un excipiente, que no es sacarosa ni seroalbumina humana, respectivamente, y sus mezclas.
ARP080102286A 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida AR066782A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93262407P 2007-06-01 2007-06-01
EP07010912A EP1997509A1 (en) 2007-06-01 2007-06-01 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US99885807P 2007-10-12 2007-10-12
EP07020025A EP2048156A1 (en) 2007-10-12 2007-10-12 Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin

Publications (1)

Publication Number Publication Date
AR066782A1 true AR066782A1 (es) 2009-09-09

Family

ID=40074591

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080102286A AR066782A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida
ARP080102287A AR066783A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080102287A AR066783A1 (es) 2007-06-01 2008-05-30 Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de toxina botulinica

Country Status (15)

Country Link
US (2) US20090028906A1 (es)
EP (2) EP2170375A1 (es)
JP (2) JP2010528999A (es)
KR (2) KR20100020972A (es)
CN (2) CN101720331A (es)
AR (2) AR066782A1 (es)
AU (2) AU2008256418A1 (es)
BR (2) BRPI0812322A2 (es)
CA (2) CA2686637A1 (es)
IL (2) IL202129A0 (es)
MX (2) MX2009012570A (es)
RU (1) RU2009149604A (es)
TW (2) TW200914039A (es)
WO (2) WO2008145359A1 (es)
ZA (2) ZA200907874B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
BRPI0923731B1 (pt) 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
CA2751311C (en) * 2009-02-19 2019-08-06 Merz Pharma Gmbh & Co. Kgaa Means and methods for manufacturing highly pure neurotoxin
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
PT2425251T (pt) * 2009-04-27 2017-11-27 Merz Pharma Gmbh & Co Kgaa Meios e métodos para a determinação da quantidade de polipéptido de neurotoxina e das suas atividades catalítica e proteolítica
BRPI1015938A2 (pt) 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
ES2688065T5 (es) * 2009-10-21 2024-10-04 Revance Therapeutics Inc Métodos y sistemas para purificar la neurotoxina botulínica no complejada
ES2810098T3 (es) * 2011-03-31 2021-03-08 Medy Tox Inc Preparación liofilizada de toxina botulínica
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
KR101357999B1 (ko) * 2012-03-20 2014-02-03 함종욱 보툴리눔 에이형 독소의 액상제품
AR103243A1 (es) * 2014-12-23 2017-04-26 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulínica
RU2722290C2 (ru) * 2015-02-03 2020-05-28 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
EP3070539A1 (fr) * 2015-03-17 2016-09-21 Omega SA Montre-bracelet comprenant un cadran muni d'index lumineux
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2020138674A1 (ko) 2018-12-26 2020-07-02 (주)케어젠 근육 이완용 조성물
MX2020014330A (es) 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
EP4501349A4 (en) * 2022-04-01 2025-07-23 Chongqing Claruvis Pharmaceutical Co Ltd BOTULINUM TOXIN PROTEIN COMPOSITION, ITS PREPARATION METHOD AND USE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
AU2005274822B2 (en) * 2004-07-26 2008-10-30 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ATE430797T1 (de) * 2005-06-17 2009-05-15 Merz Pharma Gmbh & Co Kgaa Vorrichtung und verfahren zur fermentativen herstellung biologisch wirksamer verbindungen
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica

Also Published As

Publication number Publication date
AU2008256419A1 (en) 2008-12-04
JP2010528999A (ja) 2010-08-26
MX2009012990A (es) 2010-04-01
IL202130A0 (en) 2010-06-16
US20090028906A1 (en) 2009-01-29
JP2010529000A (ja) 2010-08-26
RU2009149604A (ru) 2011-07-20
ZA200907875B (en) 2010-11-24
IL202129A0 (en) 2010-06-16
WO2008145358A1 (en) 2008-12-04
TW200902050A (en) 2009-01-16
BRPI0812322A2 (pt) 2014-11-25
KR20100020971A (ko) 2010-02-23
MX2009012570A (es) 2010-03-15
CA2686642A1 (en) 2008-12-04
BRPI0812245A2 (pt) 2014-10-21
CA2686637A1 (en) 2008-12-04
EP2164861A1 (en) 2010-03-24
WO2008145359A1 (en) 2008-12-04
CN101720331A (zh) 2010-06-02
AR066783A1 (es) 2009-09-09
TW200914039A (en) 2009-04-01
CN101687018A (zh) 2010-03-31
KR20100020972A (ko) 2010-02-23
EP2170375A1 (en) 2010-04-07
ZA200907874B (en) 2011-03-30
US20090010965A1 (en) 2009-01-08
AU2008256418A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
AR066782A1 (es) Proceso para proporcionar un relajante muscular estable a la temperatura a base del componente neurotoxico de la oxina botulinica en forma solida
UY37495A (es) Dinucleótidos cíclicos como agonistas de sting
AR069860A1 (es) Metodo para purificar un anticuerpo cd20
HUS1600005I1 (hu) Csontra irányuló lúgos foszfatáz, kitek és eljárások alkalmazásukra
DK1866414T3 (da) Inhibitorer af ribonukleotidreduktase-underenhed 2 og anvendelser deraf.
EP2046735A4 (en) SUBSTITUTED PHENYL SULFUR TRIFLUORIDE AND OTHER SIMILAR FLUORINATING SUBSTANCES
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
CL2017002184A1 (es) Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria.
CR9657A (es) Crystaline forms of 4-methyl-n-(3(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl)3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
BRPI0721503A8 (pt) composições e métodos para tratamento de um poço bloqueado por água
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
ATE477321T1 (de) Aviäre telomerase reverse transkriptase
AR050717A1 (es) Composiciones farmaceuticas
BR112017008149A2 (pt) seleção de componentes da matriz extracelular e/ou proteínas matricelulares para a viabilidade e retenção melhoradas da célula após a criopreservação
UA104712C2 (uk) Спосіб обробки бананів
BR112019001112A2 (pt) aprimoramento da criopreservação de célula com glicolipídeos
AR062123A1 (es) Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
NZ752705A (en) Dna-binding protein using ppr motif, and use thereof
AR101147A1 (es) Composiciones y métodos que comprenden una variante de xilanasa
GT200600227A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
DOP2006000268A (es) Agentes antibacterianos
BRPI0611820B8 (pt) método de identificar uma infecção por e. canis ou e. chaffeensis
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
NO20034278D0 (no) Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner
BRPI0606358A2 (pt) uso de pelo menos um aminoditiol, processo e kit para a deformação permanente dos cabelos e aminotióis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal